Move Over CBD: Rare Cannabinoids Shaking Up Cannabis And Hemp Products – Forbes

Biomedican on Forbes

Biomedican on Forbes


Forbes contributor, Amanda Siebert, analyzed the rise of rare cannabinoids, including CBG, CBN, and others in her recent article “Move Over CBD: Rare Cannabinoids Shaking Up Cannabis And Hemp Products.” As a part of this article, Max Mikheev and Dennis O’Neil of Biomedican shared our unique approach – biosynthesis of rare cannabinoids – that revolutionized the conventional approach to their production. Amanda dug into the emerging ideas to capitalize on new compounds and technologies that are way more accessible and affordable than the conventional ones.

Pain reliever – CBG (cannabigerol)

The article highlighted the possibility of making pricey compounds affordable. For instance, the quantity of a non-psychoactive compound CBG (cannabigerol) varies in numerous plants from less than one percent to fifteen percent. Plant variants with 15% CBG reduced the amount of plant matter required to make anti-inflammatory and pain reliever products such as topicals and extracts. This way, it reduced the overall cost of CBG products.

Sleep protector – CBN (cannabinol) 

Sleep deprivation is a pandemic in itself. According to the Centers for Disease Control and Prevention, one-third of adults in the United States are sleep deprived. Another rare cannabinoid – CBN helps overcome this sleep deprivation. CBN is manufactured by the breakdown of THC. This rare cannabinoid is described by researchers as a compound without heavy psychological effects, unlike THC. “CBN is more appropriate for relaxing effect without a hangover.”

Biosynthesis of rare cannabinoids

Production of rare cannabinoids without plant remodeled the conventional approaches. Dennis O’Neill, president at Biomedican, explained how the traditional grow-harvest-extract method for cannabinoids production cost much more than the novel biosynthesis method. Biosynthesis is a more reliable and natural method to grow rare pharmaceutical-grade cannabinoids that are advanced enough to yields the same product twice without contamination. The patent biosynthesis method involves utilizing a strain of yeast called yarrowia lipolytica to grow rare compounds, i.e., CBGA, CBG, THCVA, and THCV. Increasingly popular THCV has neuroprotective and appetite reduction effects and can be used for weight management and Parkinson’s disease patients.

A team of well-known researchers from Denmark Technical University, Clemson University, Imperial College of London, and Moscow State University helped Biomedican form the vision of using biosynthesis produce these cannabinoids for products such as pharmaceuticals, nutraceuticals, foods, topicals, and cosmetics. Max Mikheev narrated our idea of growing the same natural product that will cost as minimum as $5 per gram of CBG. He quoted that “We’re growing the same thing you find in the natural world, and in large quantities, so the supply chain won’t have to worry whether or not we had a good growing season.”

We invite you to break the stereotype of cannabinoids from plants and partner with us to fulfill the market’s demand for high-purity low-cost products. To learn more, please visit our website.

Publications

Contact us

Content author Dr.Saba IqbalAuthor posts

Saba Iqbal

Dr. Saba Iqbal is a contributing writer for BioMedican. She's a clinical pharmacist turned writer. Dr. Saba's education includes a doctoral degree in pharmacy (Pharm D) from the University of Sargodha, Pakistan. In search of a career that would take advantage of her medical and pharmaceutical skills, Dr. Saba found medical writing – a career path a few medical students consider. In her journey "from a medical bench to pen," she has worked with several startups for many years managing content on biotech products, pharmaceuticals, drugs, devices, and techniques. While keeping up with the latest trends in medical writing, she aims to use her writing skills to clearly communicate complex scientific, medical, and health information to the potential investor and general audience.